HeartBeam Reports Strong First Quarter 2026 Progress as Commercial Expansion and AI-Driven Cardiac Innovation Accelerate
HeartBeam, a medical technology company focused on transforming cardiac care through advanced ECG-based solutions, reported financial and operational results for the first quarter ended March 31, 2026, highlighting major progress in commercialization, artificial intelligence development, heart attack detection research, and expansion of its FDA-cleared cardiac monitoring platform.
The company achieved several strategic milestones during the quarter, including signing its first commercial partnerships, launching new pilot studies, strengthening its balance sheet through a public offering, and advancing collaborations designed to accelerate next-generation AI-powered ECG technologies. HeartBeam’s leadership emphasized that the company is entering an important growth phase as it expands its footprint across key U.S. healthcare markets.
One of the most notable developments during the quarter was HeartBeam’s initial commercial launch through partnerships with leading concierge and preventive cardiology practices. The company signed its first commercial agreement with ClearCardio™, a rapidly growing preventive cardiology organization with thousands of active members. The collaboration includes an initial phased rollout across the New York metropolitan region, Dallas, and South Florida, enabling HeartBeam to introduce its cardiac monitoring technology into high-engagement patient populations.
The company also established a commercial partnership with Atelier Health, a premier concierge medical practice based in Beverly Hills and led by physicians affiliated with Cedars-Sinai. This agreement supports HeartBeam’s expansion into Southern California and further strengthens its presence in the growing concierge healthcare sector.
Together, these partnerships establish flagship commercial sites across HeartBeam’s targeted strategic regions, including New York, Dallas, South Florida, and Southern California. According to the company, these initial deployments are expected to support scalable adoption of its technology while also helping refine physician onboarding, patient engagement, and workflow integration processes.
HeartBeam noted that these collaborations represent an important entry point into the structured direct-pay healthcare segment, which serves an estimated 5 million patients across the United States. By partnering with concierge and preventive cardiology practices, the company aims to accelerate adoption among patients seeking proactive cardiovascular monitoring and personalized care solutions.
The company also made significant progress in expanding the clinical applications of its ECG platform. During the quarter, HeartBeam enrolled the first patients in its ALIGN-ACS pilot study, which is evaluating the HeartBeam System for heart attack detection. The study focuses on patients presenting with chest pain in emergency department settings and is expected to complete enrollment rapidly due to the targeted patient population.
Management described the pilot study as an important step toward future FDA indication expansion for heart attack assessment. If successful, the technology could address a large market opportunity involving more than 20 million patients considered at risk for heart attacks annually. The company believes its portable and remote cardiac monitoring platform could eventually help physicians detect acute cardiac conditions outside traditional healthcare facilities.
HeartBeam also advanced development of its extended-wear ambulatory ECG patch technology. During the quarter, the company completed the first working prototype of an extended-wear 12-lead ECG patch designed to help detect ischemia and complex arrhythmias. In addition, the company initiated a pilot study evaluating what it describes as the first on-demand 12-lead ECG patch capable of detecting ischemia outside the clinic environment.
The patch initiative targets an estimated $2 billion market opportunity supported by established reimbursement pathways. HeartBeam believes the technology could significantly expand the capabilities of traditional ECG patch systems, which currently focus primarily on atrial fibrillation detection. By enabling ischemia detection and broader cardiac analysis, the company aims to differentiate itself within the rapidly growing remote cardiac monitoring industry.
Artificial intelligence also remained a central component of HeartBeam’s growth strategy during the quarter. The company announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai to support development and validation of next-generation AI-ECG algorithms.
The collaboration combines Mount Sinai’s expertise in artificial intelligence and clinical cardiology with HeartBeam’s proprietary 3D ECG signal collection technology. The companies plan to develop advanced AI applications focused on heart attack detection, personalized cardiac assessment, and future predictive cardiac monitoring solutions.
HeartBeam executives stated that AI-powered analytics could become a critical differentiator for the company as healthcare providers increasingly seek data-driven diagnostic tools capable of improving early detection and long-term cardiovascular monitoring.
To support its commercial growth initiatives, HeartBeam strengthened its leadership team by appointing Bryan Humbarger as Chief Commercial Officer. In his new role, Humbarger will oversee commercial strategy and execution as the company scales its technology platform and expands physician adoption nationwide.
Financially, HeartBeam reported continued efforts to manage operating expenses while advancing strategic initiatives. Research and development expenses for the first quarter of 2026 totaled $2.4 million, compared to $3.5 million during the same period in 2025. The reduction primarily reflects ongoing efforts to optimize development spending while maintaining progress across key innovation programs.
Selling, general, and administrative expenses increased slightly to $2.3 million in the first quarter of 2026, compared to $2.0 million during the prior-year quarter. The increase was largely associated with commercialization activities, operational growth, and investments supporting market expansion initiatives.
Net loss for the first quarter of 2026 improved to $4.7 million, compared to a net loss of $5.5 million during the first quarter of 2025. Net cash used in operating activities totaled $3.6 million for the three-month period ended March 31, 2026, representing a 19% decrease compared to the same period last year.
HeartBeam reported cash and cash equivalents of $2.0 million as of March 31, 2026, compared to $4.4 million at the end of 2025. However, the company subsequently strengthened its financial position through an underwritten public offering completed in April 2026. The offering generated gross proceeds of approximately $11.5 million, including the full exercise of the over-allotment option, before underwriting discounts and offering expenses.
Chief Executive Officer Robert Eno highlighted the company’s rapid operational progress and commercialization momentum during prepared remarks accompanying the earnings release.
Eno stated that HeartBeam made meaningful advances across several strategic priorities in a short period of time, including establishing flagship commercial accounts, advancing heart attack detection initiatives, expanding development of its on-demand ECG patch platform, and reinforcing its balance sheet.
He emphasized that HeartBeam’s FDA-cleared synthesized 12-lead ECG platform remains central to the company’s long-term growth strategy and is supported by strong intellectual property protections and growing clinical evidence.
Looking ahead, management said the company plans to focus on deepening adoption within flagship healthcare accounts, enhancing physician workflow integration, improving patient onboarding systems, and continuing advancements in artificial intelligence, ischemia detection, and wearable cardiac monitoring technologies throughout 2026.
HeartBeam also announced that CEO Robert Eno, CFO Timothy Cruickshank, and Chief Commercial Officer Bryan Humbarger will host a webcast and conference call to discuss first-quarter 2026 results and corporate developments.
HeartBeam is focused on transforming the detection and monitoring of critical cardiac conditions through its proprietary 3D ECG technology platform. The company developed the first cable-free device capable of collecting ECG signals from three non-coplanar directions and synthesizing them into a traditional 12-lead ECG format.
The platform is designed to enable portable cardiac monitoring that can be used outside traditional medical facilities, allowing physicians to monitor cardiac health trends, detect arrhythmias, assess acute cardiac conditions, and direct patients to appropriate care remotely.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while its 12-lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025. The company currently holds more than 20 issued patents supporting its technology platform and future development initiatives.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement
